News | April 07, 2022
Indian pharma growth likely to moderate in FY23: ICRA
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
An integrated and agile approach enables the pharmaceutical CDMO industry to simplify manufacturing as it moves from primary care medicines to specialty medicines
All intellectual-property disputes related to the market entry of Alvotech’s AVT02 (adalimumab) in the U.S. and Europe are now resolved
The Blockchain-based solution was awarded the 2021 Bionow Technical Service Award
The new facility is scheduled to start operation in the first half of 2024
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
It also secures US $ 10 million for US launch and commercialization
The launch of medical cannabis products resulted from an agreement between the two companies signed in 2021
Among patients with infectious virus at baseline, no patients who received Lagevrio had infectious virus at days 3, 5 or 10
Celerity Pharmaceuticals uses Biocon Biologics’ insulin drug substance to develop the product
Subscribe To Our Newsletter & Stay Updated
